Very low risk for recurrence seen for postmenopausal women aged 50 to 69 years who did not receive radiotherapy after breast-conserving surgery<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Dec. 7, 2023 (HealthDay News) — For postmenopausal women aged 50 to 69 years with stage 1 hormone receptor-positive breast cancer, the risk for recurrence is very low for those who do not undergo radiotherapy after breast-conserving surgery (BCS), according to a study published online Dec. 7 in the Journal of Clinical Oncology <\/em>to coincide with the annual San Antonio Breast Cancer Symposium, held from Dec. 5 to 9 in San Antonio.<\/p>\n Reshma Jagsi, M.D., D.Phil., from Emory University in Atlanta, and colleagues examined whether younger postmenopausal patients who might be successfully treated without radiotherapy could be identified by adding a genomic assay to classic selection factors. A total of 200 eligible postmenopausal patients aged 50 to 69 years with pT1N0 unifocal invasive breast cancer with margins \u00e2\u0089\u00a52 mm after BCS whose tumors were estrogen receptor-positive, progesterone receptor-positive, and HER2-negative, with Oncotype DX 21-gene Recurrence Score \u00e2\u0089\u00a418 were enrolled.<\/p>\n One hundred eighty-six patients had clinical follow-up of at least 56 months; at five years, their overall and breast cancer-specific survival rates were both 100 percent. The researchers found that the five-year freedom from recurrence was 99 percent. For the entire follow-up period, the crude rates of ipsilateral breast events were 3.3 and 3.6 percent for patients aged 50 to 59 and 60 to 69 years, respectively; the corresponding crude rates of overall recurrence were 5.0 and 3.6 percent.<\/p>\n “Although techniques of radiation treatment have improved dramatically, and it is far more efficient and tolerable now than it used to be, patients appreciate having a choice about their treatments,” Jagsi said in a statement.<\/p>\n Jagsi disclosed ties to the biopharmaceutical industry and reported serving as an expert witness.<\/p>\n Abstract\/Full Text<\/a><\/p>\n